ABBV vs ALVO: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: ABBV is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ABBV and ALVO share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ABBV and ALVO exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

AbbVie is a North Chicago-based research-driven biopharmaceutical company spun off from Abbott Laboratories in 2013. It focuses on discovering and commercializing medicines for immunology, oncology, neuroscience, and aesthetics. Its immunology franchise anchors the business: historically through Humira (adalimumab), and increasingly through Skyrizi (risankizumab) and Rinvoq (upadacitinib), which treat conditions such as plaque psoriasis, Crohn's disease, rheumatoid arthritis, and ulcerative colitis. Oncology contributes through Imbruvica (developed in collaboration with Johnson and Johnson) and Venclexta (in collaboration with Roche), while the 2020 acquisition of Allergan added Botox Therapeutic, Vraylar, and the aesthetics portfolio including Botox Cosmetic and Juvederm. Revenue is generated by selling branded pharmaceuticals at negotiated prices to wholesale distributors, specialty pharmacies, and health systems across more than 175 countries.

Full ABBV guide

Alvotech develops and manufactures biosimilars, which are approved copies of biologic medicines whose patents have run out, and then hands the selling to partners rather than building its own sales force. Teva covers the United States, Advanz Pharma covers Europe, the UK, Switzerland, Canada and Australia, Dr. Reddy's carries denosumab and is co-developing a Keytruda biosimilar, and Sandoz picked up Canadian and ANZ rights in early 2026. Five biosimilars now produce revenue: adalimumab, ustekinumab, golimumab, aflibercept and denosumab. Money arrives in two very different shapes, product supply to those partners and lumpy licensing and milestone payments, which is why half-year comparisons swing hard. First-half 2026 revenue was about $211.9 million, split almost evenly between roughly $105.9 million of product and $105.7 million of licensing, against $306.1 million a year earlier when milestones happened to land in the period.

Full ALVO guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ABBV drivers: Skyrizi and Rinvoq replacing Humira faster than expected; Neuroscience becoming a meaningful second growth engine.
• ALVO drivers: Three FDA decisions in one December week; Five products already generating cash.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The single largest structural risk is portfolio concentration: Skyrizi and Rinvoq together account for a rapidly growing share of total revenue, meaning any clinical setback, competitive entry in atopic dermatitis (where Regeneron's Dupixent holds a strong position), or government-mandated price cut under the Inflation Reduction Act could materially impair the growth outlook. For ALVO, leverage is the dominant risk: roughly $1.31 billion of borrowings against $142.8 million of cash mid-year, a net-debt-to-adjusted-EBITDA ratio above 9x at the end of 2025, and a new term loan carrying 12.50% cash interest maturing December 2027.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ABBV if you believe its drivers more; ALVO if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ABBV and ALVO guides.

ABBV. The large gap between the trailing GAAP P/E (elevated, reflecting non-cash acquired IPR and D charges on recent deals) and the forward P/E of roughly 15.7x illustrates why analysts and management prefer adjusted metrics: large upfront licensing and milestone payments depress reported earnings without reducing cash generation. On a free cash flow basis, AbbVie trades at a more modest multiple, and the PEG ratio near 0.91 suggests the consensus earnings growth rate is tracking faster than the headline valuation implies. The 2026 revenue guidance of roughly $67 billion and adjusted EPS of $14.37 to $14.57 would, if achieved, represent meaningful upward re-rating from 2025 reported figures.

ALVO. Adding roughly $1.3 billion of net debt to a $2.1 billion market cap puts enterprise value near $3.4 billion, about 17 times the midpoint of 2026 adjusted EBITDA guidance and roughly 3 times guided revenue. Those multiples only hold if the second half arrives as guided, because the first half produced about a quarter of the full-year EBITDA target. The shares have traded between $2.94 and $9.25 over the past year, a range that says more about how the market prices the regulatory outcome than about the operating business.

Headline figures (approximate, 2026-06-27): ABBV shows revenue (fy 2025, reported) ~$61.2 billion, adjusted diluted eps (fy 2025) $10.00, gaap diluted eps (fy 2025) $2.36, forward p/e (consensus fy 2026 estimate) ~15.7x; ALVO shows revenue (ttm) ~$495 million, 2026 revenue guidance ~$650M to $700M, adjusted ebitda (h1 2026) ~$46.9 million, net loss (ttm) ~$180 million.

ABBV and ALVO are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ABBV and ALVO exposure against your real portfolio. It is not an investment adviser.